A combinatorial approach for achieving CNS-selective RNAi
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Chemically modified small interfering RNAs (siRNAs) can silence genes in the central nervous system (CNS). Researchers developed anti-siRNAs to block unwanted liver gene silencing, achieving CNS-selective RNA interference for potential clinical use.
Area Of Science
- Biochemistry
- Molecular Biology
- Pharmacology
Background
- RNA interference (RNAi) is a natural process for regulating gene expression using small interfering RNAs (siRNAs).
- Oligonucleotide distribution and clearance are influenced by administration route and chemical structure, potentially causing off-target effects in organs like the liver.
- Divalent siRNAs (di-siRNAs) administered into the cerebrospinal fluid (CSF) effectively silence genes in the CNS but can accumulate in the liver.
Purpose Of The Study
- To develop a method for achieving selective gene silencing in the CNS while preventing off-target effects in the liver.
- To demonstrate that co-administration of anti-siRNAs can mitigate undesired gene modulation in specific organs.
Main Methods
- Utilized divalent siRNAs (di-siRNAs) for CNS gene silencing via CSF administration.
- Employed liver-targeting, GalNAc-conjugated anti-siRNAs as inhibitors to block off-target effects.
- Used the APOE gene as a model target to assess liver silencing and its mitigation.
Main Results
- Di-siRNAs administered into the CSF induced robust gene silencing throughout the CNS.
- Unintended di-siRNA accumulation and gene silencing occurred in the liver.
- Administration of liver-targeting anti-siRNAs successfully blocked hepatic APOE silencing without affecting CNS activity.
- Achieved fully CNS-selective gene silencing through targeted inhibition of off-target effects.
Conclusions
- Coadministration of targeted anti-siRNAs with siRNAs offers a strategy to achieve tissue-specific gene silencing.
- This approach enhances the safety and potential clinical translatability of RNA interference therapies by preventing off-target organ accumulation and activity.
- The developed method can be adapted for achieving tissue selectivity in various organ combinations beyond the CNS and liver.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
